Proceedings.

ACERUS PHARMACEUTICALS CORPORATION, ACERUS BIOPHARMA INC., ACERUS LABS INC. AND ACERUS PHARMACEUTICALS USA, LLC.

Follow
Closed
Proceeding
CCAACCAA
Filings held65
Last activity15 Jul 2024
On the record1,334 days

Early record. This matter is tracked from the court registry; its linked filings are the record, and extracted facts will appear here as its documents are processed. Still to come: a written summary; the stage tracker; capital structure; assets; estate financials; the sale process.

Case updates65 dated entries

62 earlier updates, back to 26 January 2023 subscribers.

Parties

Debtor

ACERUS PHARMACEUTICALS CORPORATION, ACERUS BIOPHARMA INC., ACERUS LABS INC. AND ACERUS PHARMACEUTICALS USA, LLC.

Monitor

EY

RecoveriesAs stated in the filings

Closed · the record states no distribution outcome.

Documents
65 filings
DateDocumentFile
Trustee's Preliminary Report, dated July 15, 2024Trustee site
Certificate of AppointmentTrustee site
Creditor PackageTrustee site
Order Closing The Chapter 15 CasesTrustee site
CCAA Termination Order, dated July 24, 2023Trustee site
Endorsement of Steele, J., dated July 24, 2023Trustee site
Book of Authorities of the Applicants, dated July 21, 2023Trustee site
Factum of the Applicants dated July 21, 2023Trustee site
The purpose of this report (the “Fifth Report”) is to provide information to the Court on the following: a) the activities of the Monitor and the Acerus Group’s operations since the fourth report of the Monitor dated June 27, 2023 (the “Fourth Report”), including the closing of the Transactions; b) the partial revocation of the failure-to-file cease trade order (“FFCTO”) granted by the Ontario Securities Commission (“OSC”); c) the Lease Disclaimer and the Keldmann Disclaimer (both as defined and discussed below); d) the Acerus Group’s receipts and disbursements for the period from June 12, 2023 to July 9, 2023, as compared to the cash flow forecast appended as Appendix “D” to the Fourth Report; and e) the Applicants’ motion for an Order (the “CCAA Termination Order”), among other things: i. approving the fees and disbursements of the Monitor and its counsel as described in this Fifth Report, including the estimated fees and disbursements of the Monitor and its counsel incurred to conclude these CCAA Proceedings or to address matters which are ancillary or incidental to these CCAA Proceedings (the “Subsequent Fees and Disbursements”); ii. approving the Fourth Report and this Fifth Report and the activities of the Monitor as set out in those reports; iii. expanding the Monitor’s powers in respect of the Applicants/Residual Cos.(as defined and discussed below); iv. approving the assignment into bankruptcy of the Applicants and authorizing, but not requiring, the Monitor to act as the trustee-in-bankruptcy of each of the Applicants; v. extending the Stay Period to the CCAA Termination Time (as defined below) or such other date as the Court may order; vi. terminating each of the Charges (as defined in the ARIO), discharging the Monitor and the CRO, and terminating these CCAA Proceedings upon the service of the Monitor’s CCAA Termination Certificate (as defined below); and vii. confirming that the Release granted in the Approval and Reverse Vesting Order applies to the CRO and Naveed Z. Manzoor in respect of liabilities which may be incurred as a result of acting as a director or officer of the Applicants/Residual CosTrustee site
Motion Record Termination of CCAA ProceedingsTrustee site
Endorsement of Justice Penny re Motion For A Stay ExtensionTrustee site
Order Re: Extension of Stay Period to July 31, 2023Trustee site
Fourth Report of the MonitorTrustee site
Extension of Stay Period - Returnable June 28, 2023Trustee site
Order (Approval and Reverse Vesting Order and Extension of Stay Proceedings)Trustee site
Order (I) Recognizing and Enforcing The CCAA Vesting Order, (II) Approving the Sale of Substantially All of the Debtors' Interests Free and Clear of Liens, Claims and Encumbrances, and (III) Granting Related ReliefTrustee site
Notice of Sale Recognition HearingTrustee site
Declaration of Elizabeth Pillon in Support of Foreign Representative's Motion for Entry of an Order (I) Recognizing and Enforcing the CCAA Vesting Order, (II) Approving the Sale of Substantially all of the Debtors' Interests Free and Clear of Liens, Claims, and Encumbrances, and (III) Granting Related ReliefTrustee site
Declaration of Naveed Z. Manzoor In Support of Foreign Representative's Motion for Entry of An Order (I) Recognizing and Enforcing the CCAA Vesting Order, (II) Approving the Sale of Substantially all of the Debtors' Interests Free and Clear of Liens, Claims, and Encumbrances, and (III) Granting Related ReliefTrustee site
Foreign Representative's Motion for Entry of An Order (I) Recognizing and Enforcing the CCAA Vesting Order, (II) Approving the Sale of Substantially All of the Debtors' Interests Free and Clear of Liens, Claims, and Encumbrances, and (III) Granting Related ReliefTrustee site
Order Pursuant to Bankruptcy Rule 9006(c) and Local Rule 9006-1(e) Shortening The Notice Period for Foreign Representative's Motion for Entry of an Order (I) Recognizing and Enforcing the CCAA Vesting Order, (II) Approving the Sale of Substantially All of the Debtors' Interests Free and Clear of Liens, Claims, and Encumbrances, and (III) Granting Related ReliefTrustee site
Approval and Reverse Vesting Order and Extension of Stay of ProceedingsTrustee site
Endorsement of Justice Penny re Reverse Vesting Order and Extension of Stay of ProceedingsTrustee site
Factum of the Applicants (Re: Approval and Reverse Vesting Order and Extension of Stay of Proceedings)Trustee site
Responding Motion Record (returnable May 30, 2023)Trustee site
Third Report of the MonitorTrustee site
Motion Record re Approval and Reverve Vesting Order and Extension of Stayof Proceedings - returnable May 30, 2023Trustee site
Endorsement of Justice Penny re Sale Approval and Vesting Order Motion Adjourned to May 30, 2023Trustee site
Stay Extension Order - to May 30, 2023Trustee site
Court Approval of SISPTrustee site
Declaration of Elizabeth Pillon In Support of Foreitn Representative's Motion for Entry of An Order (I) Recognizing and Enforcing the CCAAA SiSP Approval Order and (II) Granting Related ReliefTrustee site
Declaration of Naveed Z. Manzoor In Support of Foreitn Representative's Motion for Entry of An Order (I) Recognizing and Enforcing the CCAAA SiSP Approval Order and (II) waGranting Related ReliefTrustee site
Foreign Representative's Motion for Entry of an Order: (I) Recognizing and Enforcing the CCAA SISP Approval Order and, (II) Granting Related ReliefTrustee site
Notice of Hearing on Foreign Representative's Motion for Entry of an Order (I) Recognizing and Enforcing the CCAA SISP Approval Order and (II) Granting Related ReliefTrustee site
Notice of Sale and Investment Solication Process ("SISP") - Newspaper AdTrustee site
Order Pursuant to Bankruptcy Rule 9006(c) and Local Rule 9006-1(e) Shortening the Notice Period for Foreitn Representative's Motion for Entry of an Order (I) Recognizing and Enforcing the CCAA SISP Approval Order and (II) Granting Related ReliefTrustee site
Endorsement of Justice Conway re SISP Approval and Extension to Stay of ProceedingsTrustee site
SISP Approval and Extension to Stay of Proceedings OrderTrustee site
Factum of the Applicants (SISP Approval and Extension to Stay of Proceedings)Trustee site
Second Report of the MonitorTrustee site
SISP Approval and Extention to Stay of Proceedings - returnable Mar 9, 2023Trustee site
Order Granting Verified Petition For (I) Recognition of Foreigh Main Proceedings, (II) Recognition of Foreign Representative, (III) Recognition of Initial Order and Amended and Restated Initial Order, and (IV) Related Relief Under Chapter 15 of the Bankruptcy CodeTrustee site
Service ListTrustee site
Service List as at February 7, 2023Trustee site
Amended and Restated Initial OrderTrustee site
Endorsement of Justice Osborne re Amended and Restated Initial OrderTrustee site
First Report Of The MonitorTrustee site
Service List - as at February 1, 2023Trustee site
Motion Record re Comeback HearingTrustee site
Supplementary Factum of the ApplicantsTrustee site
List of Creditors as at January 26, 2023Trustee site
Notice of Agenda For Hearing On First Day Motions Scheduled For January 31, 2023 At 2:00 P.M. (Prevailing Eastern Time)Trustee site
Notice of First Day HearingTrustee site
Notice to CreditorsTrustee site
Acerus Biopharma Inc. - Chapter 15 Petition for Recognition of a Foreign ProceedingTrustee site
Acerus Labs Inc. - Chapter 15 Petition for Recognition of a Foreign ProceedingTrustee site
Acerus Pharmaceuticals Corporation - Chapter 15 Petition for Recognition of a Foreign ProceedingTrustee site
Acerus Pharmaceuticals USA, LLC - Chapter 15 Petition for Recognition of a Foreign ProceedingTrustee site
Order Granting Provisional Relief Pursuant To Section 1519 Of The Bankruptcy CodeTrustee site
Verified Petition For: (I) Recognition of Foreign Main Proceedings, (II) Recognition of Foreign Representative (III) Recognition of Initial Order and Amended and Restated Initial Order, and (IV) Related Relief Under Chapter 15 of the Bankruptcy CodeTrustee site
Factum of the ApplicantsTrustee site
Initial ApplicationTrustee site
Initial OrderTrustee site
Service List - as at January 26, 2023Trustee site
Proposed Monitor's Pre-Filing ReportTrustee site

Filing titles and dates are public, and so is each filing's own page. The figures read from them are for subscribers.

CiteProceedings., “ACERUS PHARMACEUTICALS CORPORATION, ACERUS BIOPHARMA INC., ACERUS LABS INC. AND ACERUS PHARMACEUTICALS USA, LLC.” (CCAA). Retrieved 20 September 2026, https://proceedings.ca/case/acerus-pharmaceuticals-corporation-acerus-biopharma-inc-acerus-labs-inc-and-acer

Sources last checked · record updated 17 August 2026 · Report a correction · Printed from proceedings.ca/case/acerus-pharmaceuticals-corporation-acerus-biopharma-inc-acerus-labs-inc-and-acer

Facts and summaries are extracted automatically from the court filings linked on each page; the filings remain the authoritative record. Suggested corrections are reviewed against the source filings.

ACERUS PHARMACEUTICALS CORPORATION et al. — CCAA | Proceedings.